This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Penumbra (PEN) closed at $181.06 in the latest trading session, marking a +0.93% move from the prior day.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.
Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.
Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now
by Benjamin Rains
DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.
Penumbra (PEN) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 22.22% and 2.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.
Penumbra (PEN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 38.89% and 4.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra Enrolls First Patient for Study on Coronary Vessels
by Zacks Equity Research
Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 28.57% and 2.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Consider Cerner (CERN) Stock
by Zacks Equity Research
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
Henry Schein Closes Acquisition of Elite Computer Italia
by Zacks Equity Research
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.
NextGen Inks Deal With Appriss Health, Boosts EHR System
by Zacks Equity Research
NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.
Intuitive Surgical to Boost da Vinci Platform With Buyout
by Zacks Equity Research
Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
by Zacks Equity Research
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
by Zacks Equity Research
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
ABT or BIO: Which Stock Has Better Potential Right Now?
by Zacks Equity Research
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.